Comparative Pharmacology
Head-to-head clinical analysis: ALA SCALP versus FLUONID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA SCALP versus FLUONID.
ALA-SCALP vs FLUONID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (PpIX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), PpIX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
Fluocinolone acetonide is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, reduction of prostaglandin and leukotriene synthesis, and suppression of inflammatory mediators.
Topical application of a 5% solution to the scalp twice daily.
0.05% cream or ointment applied topically to affected area once daily. Not to exceed 30 g per week.
None Documented
None Documented
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
3.5 hours; prolonged to 18–24 hours in severe hepatic impairment.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Renal 70% as unchanged drug, biliary/fecal 30% as metabolites.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid